Stockreport

J&J Seeks FDA Nod for Subcutaneous Tremfya as Induction Regimen in UC [Yahoo! Finance]

Johnson & Johnson  (JNJ) 
Last johnson & johnson earnings: 4/14 06:31 am Check Earnings Report
US:NYSE Investor Relations: jnj.com
PDF Tremfya (guselkumab) in ulcerative colitis (UC) indication, which would provide a more convenient alternative to the current intravenous (IV) therapy. (Source: Johnson & [Read more]